A clinical trial of the treatment will begin in spring 2023.

Researchers have developed a probiotic that, they say, is protective against amyotrophic lateral sclerosis (ALS). A clinical trial of the treatment is expected to begin in spring 2023.

The probiotic contains the bacterium Lacticaseibacillus rhamnosus HA-114. The researchers studied...